Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10964188 | Vaccine | 2015 | 13 Pages |
Abstract
Both pneumococcal vaccines are cost effective in the Peruvian context. Although the net cost of vaccination with PCV10 is lower, PCV13 prevented more deaths, pneumococcal complications and sequelae. Costs per each prevented DALY were lower with PCV13. Thus, PCV13 would be the preferred policy; PCV10 would also be reasonable (and cost-saving relative to the status quo) if for some reason 13-valent were not feasible.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Edward Mezones-Holguin, Carlos Canelo-Aybar, Andrew David Clark, Cara Bess Janusz, Bárbara Jaúregui, Seimer Escobedo-Palza, Adrian V. Hernandez, Denhiking Vega-Porras, Marco González, Fabián Fiestas, Washington Toledo, Fabiana Michel,